Clifford Dustin Rubinstein

Dr. Clifford Dustin Rubinstein

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AFAndrea L. Frump
Andrea L. Frump
MAMarjorie Albrecht
Marjorie Albrecht
BYBakhtiyor Yakubov
Bakhtiyor Yakubov
SBSandra Breuils-Bonnet
Sandra Breuils-Bonnet
VNValérie Nadeau
Valérie Nadeau
TLTim Lahm
Tim Lahm
Women with pulmonary arterial hypertension (PAH) exhibit better right ventricular (RV) function and survival than men; however, the underlying mechanisms are unknown. We hypothesized that 17β-estradiol (E2), through estrogen receptor α (ER-α), attenuates PAH-induced RV failure (RVF) by upregulating the procontractile and prosurvival peptide apelin via a BMPR2-dependent mechanism. We found that ER-α and apelin expression were decreased in RV homogenates from patients with RVF and from rats with maladaptive (but not adaptive) RV remodeling. RV cardiomyocyte apelin abundance increased in vivo or in vitro after treatment with E2 or ER-α agonist. Studies employing ER-α–null or ER-β–null mice, ER-α loss-of-function mutant rats, or siRNA demonstrated that ER-α is necessary for E2 to upregulate RV apelin. E2 and ER-α increased BMPR2 in pulmonary hypertension RVs and in isolated RV cardiomyocytes, associated with ER-α binding to the Bmpr2 promoter. BMPR2 is required for E2-mediated increases in apelin abundance, and both BMPR2 and apelin are necessary for E2 to exert RV-protective effects. E2 or ER-α agonist rescued monocrotaline pulmonary hypertension and restored RV apelin and BMPR2. We identified what we believe to be a novel cardioprotective E2/ER-α/BMPR2/apelin axis in the RV. Harnessing this axis may lead to novel RV-targeted therapies for PAH patients of either sex.

27 June 2020 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
HPHarrison Pantera
Harrison Pantera
BHBo Hu
Bo Hu
DMDaniel Moiseev
Daniel Moiseev
CDChris Dunham
Chris Dunham
JRJibraan Rashid
Jibraan Rashid
JSJohn Peter Svaren
John Peter Svaren
Copy number variation of the peripheral nerve myelin gene Peripheral Myelin Protein 22 (PMP22) causes multiple forms of inherited peripheral neuropathy. The duplication of a 1.4 Mb segment surrounding this gene in chromosome 17p12 (c17p12) causes the most common form of Charcot-Marie-Tooth disease type 1A, whereas the reciprocal deletion of this gene causes a separate neuropathy termed hereditary neuropathy with liability to pressure palsies (HNPP). PMP22 is robustly induced in Schwann cells in early postnatal development, and several transcription factors and their cognate regulatory elements have been implicated in coordinating the gene’s proper expression. We previously found that a distal super-enhancer domain was important for Pmp22 expression in vitro, with particular impact on a Schwann cell-specific alternative promoter. Here, we investigate the consequences of deleting this super-enhancer in vivo. We find that loss of the super-enhancer in mice reduces Pmp22 expression throughout development and into adulthood, with greater impact on the Schwann cell-specific promoter. Additionally, these mice display tomacula formed by excessive myelin folding, a pathological hallmark of HNPP, as have been previously observed in heterozygous Pmp22 mice as well as sural biopsies from patients with HNPP. Our findings demonstrate a mechanism by which smaller copy number variations, not including the Pmp22 gene, are sufficient to reduce gene expression and phenocopy a peripheral neuropathy caused by the HNPP-associated deletion encompassing PMP22.

25 September 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
DMDalton T. McLean
Dalton T. McLean
JMJennifer J. Meudt
Jennifer J. Meudt
LRLoren D. Lopez Rivera
Loren D. Lopez Rivera
DSDominic T. Schomberg
Dominic T. Schomberg
DPDerek M. Pavelec
Derek M. Pavelec
CRClifford Dustin Rubinstein
Clifford Dustin Rubinstein
Neurofibromatosis Type 1 (NF1) is one of the most common genetically inherited disorders that affects 1 in 3000 children annually. Clinical manifestations vary widely but nearly always include the development of cutaneous, plexiform and diffuse neurofibromas that are managed over many years. Recent single-cell transcriptomics profiling efforts of neurofibromas have begun to reveal cell signaling processes. However, the cell signaling networks in mature, non-cutaneous neurofibromas remain unexplored. Here, we present insights into the cellular composition and signaling within mature neurofibromas, contrasting with normal adjacent tissue, in a porcine model of NF1 using single-cell RNA sequencing (scRNA-seq) analysis and histopathological characterization. These neurofibromas exhibited classic diffuse-type histologic morphology and expected patterns of S100, SOX10, GFAP, and CD34 immunohistochemistry. The porcine mature neurofibromas closely resemble human neurofibromas histologically and contain all known cellular components of their human counterparts. The scRNA-seq confirmed the presence of all expected cell types within these neurofibromas and identified novel populations of fibroblasts and immune cells, which may contribute to the tumor microenvironment by suppressing inflammation, promoting M2 macrophage polarization, increasing fibrosis, and driving the proliferation of Schwann cells. Notably, we identified tumor-associated IDO1+/CD274+ (PD-L1)+ dendritic cells, which represent the first such observation in any NF1 animal model and suggest the role of the upregulation of immune checkpoints in mature neurofibromas. Finally, we observed that cell types in the tumor microenvironment are poised to promote immune evasion, extracellular matrix reconstruction, and nerve regeneration.

7 April 2025 in G3: Genes, Genomes, Genetics
Verified
Journal Article
Open access
AVAlex C Veith
Alex C Veith
JMJennifer J Meudt
Jennifer J Meudt
JRJamie Reichert
Jamie Reichert
JFJennifer M Frank
Jennifer M Frank
DPDerek M Pavelec
Derek M Pavelec
MBMark E Berres
Mark E Berres
Porcine biomedical models have emerged as valuable tools in biomedical research due to their physiological, anatomical, metabolic, immunological, and genetic similarities to humans. As a result, they offer greater relevance for translational studies than rodent models. Moreover, compared to nonhuman primates, porcine models are more cost-effective, easier to manipulate genetically, and raise fewer ethical concerns. However, the conventional breeds of swine most commonly used in research have rapid growth rates, which lead to logistical challenges such as increased space requirements, making them impractical as biomedical models. The Wisconsin Miniature SwineTM (WMSTM) was developed to address these shortcomings. The WMSTM porcine model grows slower, reaching and maintaining human sizes at adulthood. The model was also specifically designed to possess more human-like physiology that allows for easy modeling of comorbidities like obesity and metabolic syndrome that affect a large portion of the human population affected by chronic diseases. Thus, WMS™ is an ideal porcine gene editing platform for modeling complex multifactorial diseases. Here, we present the first draft genome assembly representative of the WMSTM line. The primary assembly was generated with ∼20× coverage of long reads from Oxford Nanopore Technologies and independently error-corrected using 23× Pacific Biosciences reads. Arima Genomics Hi-C data were used to improve contiguity. Largely congruent with the existing Sus scrofa genome, we also show the utility of WMSTM as a model through comparisons between 2 WMSTM genes and human homologs. Finally, we show the utility of genotyping by sequencing across WMSTM herds. The WMSTM genome generated here is highly complete and supports investigators utilizing WMSTM in biomedical research.

19 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SDSidney S. Dicke
Sidney S. Dicke
CRClifford Dustin Rubinstein
Clifford Dustin Rubinstein
JSJames M. Speers
James M. Speers
MBMark E. Berres
Mark E. Berres
DPDerek M. Pavelec
Derek M. Pavelec
MZMartin T. Zanni
Martin T. Zanni
Transgenic rodent models for human diseases have been widely used over the past 50 years and are a mainstay of many biomedical research programs. Oftentimes the sequence of the transgenic segment of DNA is carefully designed but incorporation of this DNA into the host genome is less well understood. Structural variation and insertional mutagenesis may occur at transgenic insertion sites. Here, we present a robust workflow including identification of the transgene locus via selective Illumina sequencing followed by Cas9-mediated target DNA enrichment of the locus, which successfully identified beginning and end sites of a large transgenic insertion into a murine model for human amylin-induced type II diabetes. Enriched sequences were mapped via Oxford Nanopore sequencing. Although the insertion was too long for a single mapped genetic sequence to encompass, the method provided multiple insights relevant to the animal model: a minimum number of forward- and reverse-facing transcript copies as well as characterization of an inversion point within the insertion site. The insertion start point containing both murine and human DNA was used to identify and separate animals hemizygous for the transgenic insertion from homozygous animals. This identification could be performed early in the rodent life cycle prior to maturation (i.e. breeding age), thus allowing for management of colony phenotypes and eliminating the need to “genotype by phenotype” later on (onset of amylin-induced type II diabetes does not occur until ~8-10 weeks of age for this model). We further confirmed our homozygous diabetic mice function the same as colonies established in other labs and present full antibody and fluorescent-staining protocols (available in SI). Lastly, we note that, due to our genotyping, a novel animal was identified within our colony: non-diabetic homozygous mice. Indeed, only 37% of homozygous mice bred in our colony became diabetic. AUTHOR SUMMARY (for broad audience) Transgenic rodent models are important to studying human diseases. When creating a new rodent model, one may insert new DNA into a well-characterized background genome. However, it is oftentimes not known where the new DNA was incorporated, how many times it was incorporated, or if any coding sequences or regulatory elements within native DNA were disrupted. Here, we have developed a method to characterize transgenic animals, and have applied it to a popular model for studying human amylin-induced type II diabetes.

9 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BNBrian Na
Brian Na
CRClifford Dustin Rubinstein
Clifford Dustin Rubinstein
JMJennifer Meudt
Jennifer Meudt
FRFausto Rodriguez
Fausto Rodriguez
BLBrent Lehman
Brent Lehman
MGMarco Giovannini
Marco Giovannini
Background and Objectives: Among CNS malignancies arising in infancy, ATRT stands out as the most frequently diagnosed in children younger than six months. Disruption of the SMARCB1 gene underlies the overwhelming majority of cases. Progress toward effective treatment has been hampered by two persistent challenges. Current mouse models, while informative, fall short of reproducing the full clinical and biological picture of human ATRT, and their ability to predict therapeutic outcomes in patients remains uncertain. Compounding this, the rarity of the disease makes it difficult to assemble patient cohorts of sufficient size for meaningful clinical trials. At the molecular level, germline loss of SMARCB1 exons 4 and 5 has emerged as a particularly penetrant predisposing event, with affected individuals presenting at an earlier age than those harboring other mutation types. The porcine SMARCB1 gene offers a compelling basis for translational modeling as its protein product is identical to the human ortholog at every amino acid position across isoforms, a degree of conservation that exceeds what is seen in the mouse. Methods: Thus, we hypothesized that germline deletion of exons 4 and 5 would predispose heterozygote swine to ATRT development. In this manuscript, we describe the creation of an ATRT porcine model through a CRISPR/Cas9 mediated gene-editing approach. Results: 15 piglets were produced, two of which had confirmed SMARCB1 targeted excisions. However, none developed tumors. To induce further tumorigenicity, one pig with confirmed exons 4 and 5 excision was crossed with a pig with TP53 exon 2 truncation. In total, 11 piglets were born, of which one contained the original excision without a TP53 mutation. This piglet developed a spinal mass at the T1 level. Conclusion: To our knowledge, this is the first ATRT porcine model ever developed and provides proof-of-concept feasibility for large animal modeling of SMARCB1-deficient rhabdoid tumors. These findings support the continued development of porcine RTPS-1 models toward preclinical application.